Correlation Engine 2.0
Clear Search sequence regions


  • calcium (1)
  • cellular (1)
  • genes (1)
  • genes r (1)
  • homeostasis (1)
  • humans (1)
  • ischemia (6)
  • panax (1)
  • protopanaxadiol (1)
  • regulates (1)
  • Sizes of these terms reflect their relevance to your search.

    Ischemia-reperfusion injury (IRI) represents a prevalent pathological phenomenon. Traditional treatment approaches primarily aim at restoring blood supply to ischemic organs, disregarding the consequent damage caused by IRI. Belonging to the class of protopanaxadiol ginsenosides that are found in Panax ginseng, ginsenoside Rd (GSRd) demonstrates notable safety alongside a diverse range of biological functions. Its active components exhibit diverse pharmacological effects, encompassing anti-inflammatory, anti-tumor, neuroprotective, cardiovascular-protective, and immune-regulatory properties, making it a promising candidate for addressing multiple medical conditions. GSRd shields against I/R injury by employing crucial cellular mechanisms, including the attenuation of oxidative stress, reduction of inflammation, promotion of cell survival signaling pathways, and inhibition of apoptotic pathways. Additionally, GSRd regulates mitochondrial function, maintains calcium homeostasis, and modulates the expression of genes involved in I/R injury. This review seeks to consolidate the pharmacological mechanism of action of GSRd within the context of IRI. Our objective is to contribute to the advancement of GSRd-related pharmaceuticals and provide novel insights for clinicians involved in developing IRI treatment strategies. Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

    Citation

    Qiupeng Feng, Lijing Ling, Hua Yuan, Zhiqiang Guo, Jin Ma. Ginsenoside Rd: A promising target for ischemia-reperfusion injury therapy (A mini review). Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024 Feb;171:116111

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38181712

    View Full Text